Effects of SR141716A on Cognitive and Depression-Related Behavior in an Animal Model of  Premotor Parkinson's Disease by Tadaiesky, M. T. et al.
SAGE-Hindawi Access to Research
Parkinson’s Disease
Volume 2010, Article ID 238491, 6 pages
doi:10.4061/2010/238491
Research Article
Effectsof SR141716A on Cognitive andDepression-Related
Behavior in an Animal Model of Premotor Parkinson’s Disease
M. T.Tadaiesky,1 P. A. Dombrowski,2 C.DaCunha,2 andR.N. Takahashi1
1Departamento de Farmacologia, Centro de Ciˆ encias Biol´ ogicas, Universidade Federal de Santa Catarina (UFSC),
Campus Universit´ ario, Trindade, Bloco D/CCB, P.O. Box 476, 88040-970 Florian´ opolis, SC, Brazil
2Laborat´ orio de Fisiologia e Farmacologia do Sistema Nervoso Central, Setor de Ciˆ encias Biol´ ogicas,
Universidade Federal do Paran´ a (UFPR), Centro Polit´ ecnico, 81531-980 Curitiba, PR, Brazil
Correspondence should be addressed to R. N. Takahashi, takahashi@farmaco.ufsc.br
Received 25 March 2010; Revised 16 July 2010; Accepted 31 August 2010
Academic Editor: Alan R. Crossman
Copyright © 2010 M. T. Tadaiesky et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
A previous study from our laboratory revealed that moderate nigral dopaminergic degeneration caused emotional and cognitive
deﬁcits in rats, paralleling early signs of Parkinson’s disease. Recent evidence suggests that the blockade of cannabinoid CB1
receptorsmightbebeneﬁcialtoalleviatemotorinhibitiontypicalofParkinson’sdisease.Here,weinvestigatedwhetherantagonism
of CB1 receptors would improve emotional and cognitive deﬁcits in a rat model of premotor Parkinson’s disease. Depression-
like behavior and cognition were assessed with the forced swim test and the social recognition test, respectively. Conﬁrming
our previous study, rats injected with 6-hydroxydopamine in striatum presented emotional and cognitive alterations which were
improved by acute injection of SR141716A. HPLC analysis of monoamine levels demonstrated alterations in the striatum and
prefrontal cortex after SR141716A injection. These ﬁndings suggest a role for CB1 receptors in the early symptoms caused by
degeneration of dopaminergic neurons in the striatum, as observed in Parkinson’s disease.
1.Introduction
Agrowing body ofevidencesuggeststhatcognitive andemo-
tional symptoms can precede the classical motor symptoms
of Parkinson’s disease (PD). Epidemiological, pathological,
and clinical studies have provided data in favor of the exis-
tence of this premotor phase of PD [1]. Premotor symptoms
in PD include mild emotional and cognitive dysfunctions.
During this phase, the neuropathological injuries progress
withoutconcomitantmotorimpairments[2].Whencardinal
motorsigns(bradykinesia,resttremor,andrigidity)required
for PD diagnosis appear, about 60% of dopaminergic
neurons in the substantia nigra have been lost, and striatal
dopamine content has been reduced by 60%−80% [3].
Recently, we have developed a premotor model of PD in
rats, in which emotional and cognitive deﬁcits occur in
the absence of motor alterations [4]. In particular, we
have shown that the bilateral intrastriatal injection of 6-
hydroxydopamine (6-OHDA) in adult rats increases immo-
bilitytimeintheforcedswimtestoneweekafterdrugadmin-
istration, whereas discrimination impairments in the social
recognition test appear three weeks after 6-OHDA injection.
Endocannabinoids—that is, anandamide and 2-arachi-
donoylglycerol—are synthesized on demand through cleav-
age of membrane phospholipids and act as retrograde
messengers at central synapses, regulating a number of phys-
iological functions, including emotionality and cognition [5,
6].ThesemoleculesbindtotheCB1 cannabinoidreceptoron
presynaptic axon terminals to regulate ion channel activity
and inhibit neurotransmitter release [7]. The evidence that
the endocannabinoid transmission is overactive in the basal
ganglia of humans aﬀected by PD [8] and in rat models
of PD [9, 10] suggests that the blockade of cannabinoid
CB1 receptors might be beneﬁcial to alleviate PD symptoms.
In fact, evidence from nonhuman primates and rodents
has shown that the administration of SR141716A improves
m o t o rs y m p t o m si nm o d e l so fP D[ 11–14]. These data
suggest that CB1 receptor-mediated transmission plays a
functional role in motor alterations developed in the course
of the disease. However, to the best of our knowledge, the2 Parkinson’s Disease
eﬀects of CB1 receptor antagonism in the early phase of this
disorder have not yet been studied.
The CB1 receptors are densely expressed in brain areas
controlling emotional and cognitive processes, such as the
limbic system and the prefrontal cortex [15]. Therefore,
it is possible that the endocannabinoid system mediates
the emotional and cognitive alterations in this degenerative
disease. For this reason, the present experiments investigated
whether the cannabinoid system inﬂuences emotional and
cognitive alterations in a model of early PD and whether the
CB1 antagonist SR141716A reduces the 6-OHDA damaging
eﬀects in depression-like behavior and memory function in
rats.
2. Methods
2.1. Animals. A total of forty adult (3 months-old) male
Wistar rats were used in the forced swim test, while thirty-
two adult and six juvenile (1 month-old) male Wistar rats
were used in the social recognition test. The animals were
housed in a room with controlled photoperiod (07:00−19:00
lights on) and temperature (23 ±1◦C). They had free access
to standard food and tap water. All procedures used in the
present study complied with the guidelines on animal care of
the UFSC Ethics Committee on the Use of Animals, which
follows the “Principles of laboratory animal care” from
NIH.
2.2. Intrastriatal Injection of 6-OHDA. The procedure used
to induce moderate dopaminergic degeneration in rats was
based on the model previously described by us [4] using
intrastriatal 6-OHDA injection. All surgical procedures were
conducted with aseptic technique. 6-OHDA (12μgp e r
injection, diluted in 0.9% NaCl, supplemented with 0.1%
ascorbicacid,injectionvolume2.5μlattherateof0.5μl/min;
Sigma, USA) was injected over 5 minutes bilaterally into
the ventrolateral area of the dorsal striatum. Stereotaxic
infusion followed the coordinates of the Paxinos and Watson
[16] atlas: AP: 1.1mm, ML: ±3.2mm, and DV: −7.2mm
from bregma and dura, using a Hamilton 10μl syringe
with a 26-gauge needle connected to a 30-gauge cannula.
Following injection, the cannula was left in place for 2
minutes before being retracted to allow complete diﬀusion
of the drug. All animals were treated with i.p. injection of
20mg/kg desipramine (diluted in 0.9% NaCl, Sigma, USA)
30 minutes before surgery, in order to protect noradrenergic
terminals from 6-OHDA toxicity. The stereotaxic surgery
was performed under ketamine (15mg/kg, Dopalen; Agri-
brands)/xylazine (2.5mg/kg, Rompun; Bayer) anesthesia.
Sham-operated rats were submitted to the same protocol
except that vehicle was injected instead of 6-OHDA. Our
previous study [4] showed that emotional and cognitive
alterations were time dependent in this rat model of PD.
Therefore, the behavioral experiments were carried out
one (forced swim test) and three (social recognition test)
weeks after surgery. Subgroups of 4−8 animals were killed
by decapitation immediately following behavioral tests for
neurochemical analysis.
2.3. Forced Swim Test. The procedure was previously
described by Porsolt et al. [17] and established as a standard
procedure in our laboratory [4]. Rats were divided into
ﬁve equal groups (n = 8). Beginning about a week after
surgery, the rats were acclimatized to the experimental room
for at least 30 minutes before test. Rats were placed in
individual cylinders (40cm in height and 17cm in diameter)
containing water (water depth was 30cm; 25 ±1◦C). Two
swimmingsessionswereconducted(aninitial15-minpretest
followed by a 5-min test 24 hours later). SR141716A (0.5,
1, and 3mg/kg, dissolved in saline with 10% DMSO plus
0.1% Tween 80, Sanoﬁ-Aventis, France) and vehicle were
administered by i.p. route 30 minutes before the second
session of forced swimming. The total immobility time was
manually scored for 5 minutes. Immobility was deﬁned as
motionless ﬂotation, except for those movements necessary
to keep the rat’s head above the water.
2.4. Social Recognition Test. Short-term social memory was
assessed with the social recognition task as previously
established in our laboratory [4, 18]. Around three weeks
following surgery, 6-OHDA-injected and sham rats were
housed individually in standard plastic cages (42 × 34 ×
17cm) and were used after three days of habituation to their
new environment. Each animal was injected with the CB1
antagonist (0.5 and 1mg/kg) or vehicle 30 minutes before
the social recognition memory test (n = 8). The test was
scored in an observation room, to which the rats had been
habituated for 30 minutes before the test began. All juveniles
were isolated in individual cages for 30 minutes prior to
the beginning of the experiment. The social recognition test
consisted of two successive 5-minute presentations separated
by a 30-minute interval, where a juvenile rat was placed
in the home cage of the isolated adult rat. Time spent
investigating the juvenile (nosing, sniﬃng, grooming, or
pawing) was recorded during each session. At the end of the
ﬁrst presentation, the juvenile rat was removed and kept in
an individual cage during the delay period and re-exposed to
the adult rat after 30 minutes.
2.5. Neurochemical Study. For determining DA, 3,4-dihydro-
xyphenylacetic acid (DOPAC), homovallinic acid (HVA),
NA, and 5-HT contents in brain, the rats were killed by
decapitation one and three weeks after 6-OHDA administra-
tion.
The rats were decapitated, brains were immediately
removed, and striatum, prefrontal cortex, and hippocampus
were freshly dissected, frozen in liquid nitrogen, and stored
at −70
◦C. The concentrations of DA, DOPAC, HVA, NA,
and 5-HT in striatum, prefrontal cortex, and hippocampus
were assayed by reverse-phase HPLC with electrochemical
detection (ED). The system consisted of a Synergi Fusion-RP
C-18reverse-phasecolumn(150 ×4.6mmi.d.,4μmpartic le
size) ﬁtted with a 4 × 3.0mm precolumn (SecurityGuard
Cartridges Fusion-RP), an electrochemical detector (ESA
Coulochem III Electrochemical Detector) equipped with a
guard cell (ESA 5020), with the electrode set at 350mV and
a dual electrode analytical cell (ESA 5011A); and a LC-20ATParkinson’s Disease 3
pump (Shimadzu) equipped with a manual Rheodyne 7725
injectorwitha20μlloop. The columnwasmaintained inside
a temperature-controlled oven (25
◦C, Shimadzu). The cell
had two chambers in series: each chamber included a porous
graphite colorimetric electrode, a double counter electrode,
and a double reference electrode. Oxidizing potentials were
set at 100mV for the ﬁrst electrode and at 450mV for the
second electrode. DA, DOPAC, HVA, NA, and 5-HT were
detected at the second electrode. The tissue samples were
homogenized with an ultrasonic cell disrupter (Sonics) in
0.1Mperchloricacidcontainingsodiummetabisulﬁte0.02%
and internal standard. After centrifugation at 10000×gf o r
30 minutes at 4◦C, 20μl of the supernatant was injected
into the chromatograph. The mobile phase used at a ﬂow
rate of 1ml/min had the following composition: 20g citric
acid monohydrate (Merck), 200mg octane-1-sulfonic acid
sodium salt (Merck), 40mg ethylenediaminetetraacetic acid
(EDTA) (Sigma), and 900ml HPLC-grade water. The pH of
the buﬀer running solution was adjusted to 4.0 then ﬁltered
througha0.45μmﬁlter.Methanol(Merck)wasaddedtogive
a ﬁnal composition of 10% methanol (v/v). The peak areas
of the external standards were used to quantify the sample
peaks.
2.6. Statistics. Statistically signiﬁcant diﬀerences in the
forced swim test were assessed by one-way analysis of
variance (ANOVA), followed by Newman-Keuls post hoc
test. Two-way repeated-measure ANOVA was used in the
social recognition test, followed by Bonferroni’s test for
multiple comparisons. Statistical analysis of HPLC measures
was carried out by unpaired Student’s t-test. All values were
expressedasmean ±SEM.Statisticalsigniﬁcancewasdeﬁned
as P ≤ .05.
3. Results
In the forced swim test (Figure 1), one-way ANOVA revealed
an increase in immobility time compared to the sham group
(F4,50 = 4.01; P < .05). Acute treatment with SR141716A
(3mg/kg, i.p.) reverted the increase in immobility time
induced by the 6-OHDA treatment.
After the forced swim test, the neurotransmitter levels of
the brain striatum, prefrontal cortex, and hippocampus were
measured in the 6-OHDA-treated rats and the 6-OHDA-
treated rats that received the eﬀective dose of SR141716A
(3mg/kg). The measures of brain monoamine levels showed
a signiﬁcant increase in the levels of DA (t6 = 2.28; P < .05),
DOPAC (t6 = 2.35; P < .05), and HVA (t6 = 2.18; P < .05)
in the 6-OHDA-lesioned rats treated with SR141716A. No
signiﬁcant diﬀerence was found in the striatal levels of NA
(t6 = 1.38; P > .05) and 5-HT (t6 = 1.51; P > .05) and
in the levels of DA, DOPAC, HVA, NA, and 5-HT in the
prefrontal cortex and hippocampus of the 6-OHDA-lesioned
rats treated with SR141716A compared to the 6-OHDA-
lesioned rats that received vehicle. Data are shown in Table 1.
Inthesocialrecognitiontestprocedure,two-wayANOVA
(treatment versus juvenile presentation) revealed no signif-























Figure 1: Eﬀects of acute administration of SR141716A (0.5, 1,
and 3mg/kg), i.p. 30 minutes before the second session of forced
swim test on 6-OHDA-treated rats. Results are expressed as mean
immobility time ± SEM in comparison to sham controls. Statistical
analysis was performed by one-way ANOVA followed by Newman-
Keuls post hoc test. ∗P ≤ .05 compared to the sham group (n = 8
per group).
However, it indicated a signiﬁcant eﬀect for drug treatment
(F3,32 = 27.3; P < .0001) and for juvenile presentation, that
is, the second presentation of the juvenile rat (F3,32 = 8.0; P
< .0001). Bonferroni’s post hoc test showed that 6-OHDA-
treated rats presented a clear impairment of the juvenile
recognition ability in comparison to sham rats, since the 6-
OHDA group spent as much time investigating the juvenile
rat during the second encounter as they did on the ﬁrst
exposure. 6-OHDA + SR groups spent less time investigating
the juvenile rat during the second exposure compared to the
ﬁrst one. Data are shown in Figure 2.
After the social recognition test, the neurotransmitter
levels of the brain striatum, prefrontal cortex, and hip-
pocampus were measured in the 6-OHDA-treated rats and
the 6-OHDA-treated rats that received the eﬀective dose of
SR141716A (0.5mg/kg). NA (t6 = 3.09; P < .05) and 5-
HT (t6 = 2.44; P = .05) levels in the prefrontal cortex were
signiﬁcantly increased in the SR-treated group. There were
no signiﬁcant diﬀerences between the two groups in the
striatum and hippocampus (Table 2).
4. Discussion
Rats with bilateral 6-OHDA lesions of the nigrostriatal path-
way displayed depressive-like behavior and social memory
impairment, modeling the pathophysiology of nonmotor
a l t e r a t i o n st h a to c c u re a r l yi nP Dp a t i e n t s[ 1]. The evidence
of an increase in the endocannabinoid transmission in the
basal ganglia in patients and animal models of this disease
[8, 10] supports the potential of SR141716A or other CB1
receptor antagonists to alleviate PD symptoms. The data
found in this paper conﬁrm this hypothesis, since we showed
that blockade of CB1 receptors signiﬁcantly attenuated 6-
OHDA-induced impairments in the forced swim and social4 Parkinson’s Disease
Table 1: Eﬀects of acute administration of SR141716A (3mg/kg) i.p. on neurotransmitter levels in the striatum, prefrontal cortex, and
hippocampusoneweekafter6-OHDAadministration.Resultsareexpressedasmean ±SEMincomparisontothe6-OHDAgroup.Statistical
analysis was performed by unpaired Student’s t-test.
Brain region Group Content (ng/mg protein)
DA DOPAC HVA NA 5-HT
Striatum 6-OHDA 1685 ± 253.6 932.1 ± 101.7 600.8 ± 111.1 119.5 ± 7.5 228.5 ± 15.4
6-OHDA + SR 2869 ± 451.7∗ 1491 ± 214∗ 1043 ± 169.6∗ 135.1 ± 8.4 275.3 ± 26.5
Prefrontal cortex 6-OHDA 17.7 ± 6.8 20 ± 8.9 23.02 ± 8.7 144.2 ± 29.5 266.9 ± 68.1
6-OHDA + SR 8.7 ± 1.9 23.7 ± 7.9 24.24 ± 11.2 155.9 ± 7.9 387.6 ± 95.5
Hippocampus 6-OHDA 30.9 ± 1.9 22.2 ± 2.5 516.4 ± 493.7 237.8 ± 34.3 104 ± 34
6-OHDA + SR 30.4 ± 1.3 18.2 ± 34 5 ± 6.2 273.8 ± 42.2 167.2 ± 50.2
∗P ≤ .05 compared to the 6-OHDA group (n = 4p e rg r o u p ) .
Table 2: Eﬀects of acute administration of SR141716A (0.5mg/kg) i.p. on neurotransmitter levels in the striatum, prefrontal cortex, and
hippocampus three weeks after 6-OHDA administration. Results are expressed as mean ± SEM in comparison to the 6-OHDA group.
Statistical analysis was performed by unpaired Student’s t-test.
Brain region Group Content (ng/mg protein)
DA DOPAC HVA NA 5-HT
Striatum 6-OHDA 1364 ± 337.2 1266 ± 223 777.2 ± 107.8 131 ± 19.5 227.9 ± 15.7
6-OHDA + SR 2099 ± 759.9 1190 ± 61.8 828.4 ± 74.4 125.7 ± 6.5 248.1 ± 32.2
Prefrontal cortex 6-OHDA 16.8 ± 4.1 20.2 ± 11.7 35.1 ± 7.5 104.9 ± 29 198.4 ± 107.1
6-OHDA + SR 17.1 ± 4.7 12.3 ± 5.4 42.5 ± 5.3 208.7 ± 16.6∗ 467.3 ± 24.9∗
Hippocampus 6-OHDA 23.4 ± 7.8 17.6 ± 2.8 53.9 ± 14.2 195.9 ± 44.4 116.4 ± 59.6
6-OHDA + SR 28 ± 4.4 20.3 ± 2.5 32.8 ± 8.5 297.5 ± 28.2 165.6 ± 41.6
∗P ≤ .05 compared to the 6-OHDA group (n = 4p e rg r o u p ) .
recognition tests. This was accompanied by an increase in
DA levels in the striatum and NA and 5-HT levels in the
prefrontal cortex.
In the forced swim test, 6-OHDA-treated rats displayed
a greater tendency toward despair behavior compared to
sham animals and those treated with SR141716A, therefore
suggesting that the blockade of CB1 receptors restores
the normal coping response when animals are exposed to
inescapable aversive stimuli. The reduction of 6-OHDA-
induced increase in immobility in the forced swim test by
SR141716A was evident at the dose of 3mg/kg but not at
lower doses (0.5 and 1mg/kg), suggesting that low doses
of this CB1 antagonist may not be suﬃcient to induce
antidepressant-like eﬀect in this animal model of PD. It
must be conceded, however, that rimonabant can induce
hypermotility in rodents at high doses, and this could have
aﬀected the outcome of our results. Nevertheless, the present
evidenceagreeswiththeantidepressant-likeactivityreported
by Griebel et al. [19], in which SR141716A was shown to
reduce immobility time in the forced swim test at the dose
of 3mg/kg, but not at 1mg/kg in rats.
Infact,althoughthis,toourknowledge,is theﬁrstreport
on the behavioral action of a CB1 receptor antagonist in
a model of PD-associated depressive symptoms, the proﬁle
of CB1 antagonists on emotionality has been demonstrated
in other rodent models of depression. Antidepressant-like
eﬀects have been established in models using mice, rats, and
gerbils, and in models using diﬀerent dependent measures
[19–21]. Conﬁrmatory evidence of the involvement of CB1
receptorsintheantidepressant-likeeﬀectsofSR141716Aand
another CB1 antagonist, AM251, comes from their receptor
speciﬁcity for CB1 receptors and from pharmacological
agonist interaction studies. Thus, the direct-acting CB1
receptor agonist CP55940 prevented the antidepressant-like
eﬀects of AM251. Another crucial piece of data tying CB1
receptors to the antidepressant-like mechanism of action
of these compounds comes from the demonstration that
CB1 receptor-null mice do not display the antidepressant-
like eﬀects of AM251 [20], demonstrating the importance
of this receptor to the antidepressant-like eﬀect of these
cannabinoid antagonists.
Our results suggest that the mechanisms underlying the
antidepressant-like eﬀects of SR141716A possibly involve
restoration of dopamine levels in the striatum, since acute
administration of 3mg/kg of SR141716A produced eleva-
tions in DA, DOPAC, and HVA levels in the striatum of 6-
OHDA-treated rats. In line with this are the ﬁndings from
our previous study showing that the increase in immobility
time in the forced swim test after 6-OHDA treatment was
accompanied by a reduction in the levels of DA and its
metabolites in the striatum [4]. The increase in the striatal
levels of DA was most probably due to the blockade of
CB1 receptors localized on striatonigral GABAergic neurons



































Figure 2: Eﬀects of acute administration of SR141716A (0.5 and
1mg/kg) i.p. 30 minutes before social recognition test on 6-OHDA-
treatedrats.Resultsareexpressedasmeaninvestigationtime ±SEM
in comparison to sham controls. Statistical analysis was performed
by two-way repeated-measure ANOVA followed by Bonferroni’s
post hoc test. ∗P ≤ .05 compared to the ﬁrst juvenile presentation
(n = 8 per group).
on nigrostriatal dopaminergic projections. In fact, nigrostri-
atal dopaminergic neurons do not contain CB1 receptors,
at least in the adult brain, although these receptors are co-
localized with D1 and D2 dopaminergic receptors in striatal
projections [22].
Interestingly, the 0.5mg/kg SR141716A administration
led to a signiﬁcant increase in NA and 5-HT levels in
the prefrontal cortex, but caused no alterations in striatal
neurotransmitters. At the dose of 3mg/kg, however, DA
and its metabolites levels were signiﬁcantly increased in
striatum, while no alterations were seen in prefrontal cortex
neurotransmitter levels. This divergent increase in neuro-
transmitter levels in diﬀerent brain structures seems to be
caused by the doses used in this study and deserves to be
better investigated, perhaps employing other doses of this
CB1 antagonist in both 6-OHDA and sham animals.
Despite the strong evidence indicating a beneﬁcial eﬀect
of CB1 receptor antagonists in depression, the data obtained
sofardonotcompletelysupportthisassumptionsince,while
we and others [19–21] have demonstrated that SR141716A
might be eﬀective to reduce depressive-like symptoms in
animal models, this CB1 antagonist was withdrawn from the
market as an antiobesity drug because of its prodepressant
eﬀects. On the other side, in a clinical trial with SR141716A
in schizophrenic patients [23], in which the drug did not
aﬀect the eﬃcacy of endpoints, no adverse eﬀects on mood
and anxiety were reported. Clinical investigation speciﬁcally
designed to address the antidepressant potential of this
mechanism is, therefore, the only resolution to the question
of eﬃcacy.
The acute SR141716A eﬀect on short-term memory
functioning in this model of premotor PD was assessed using
the social recognition test. Social recognition memory bases
on olfactory cues and represents a form of olfactory short-
term memory. In this task, if the delay period is less than 40
minutes,theadultmaleratusuallydisplaysrecognitionofthe
juvenile rat by signiﬁcantly reducing the social investigation
time during the second presentation compared to the ﬁrst
one.Theabilityofsocialdiscriminationwasdisruptedinrats
treated with 6-OHDA, an eﬀect reversed by SR141716A.
It is consistent that CB1 cannabinoid receptors are
involved in cognitive processes including memory in both
human and animals [24–26]. A study from Micale et al.
[27] showed that SR141716A counteracted amnesic eﬀects
in beta amyloid-injected mice, an Alzheimer’s disease model,
strengthening the proposal role of SR141716A on the
treatment of neurodegenerative diseases.
Terranova et al. [28] previously demonstrated that
SR141716A facilitates short-term memory in the social
recognition test. Here, we extend these data by showing
that SR141716A is able to improve short-term recognition
memory in 6-OHDA-lesioned animals. It can therefore be
hypothesized that this drug may be useful to treat memory
deﬁcits associated with PD. In our previous study [4], social
recognition deﬁcits were accompanied by alterations in
neurotransmitter levels in the prefrontal cortex. Here, those
results further imply this area in this kind of memory, since
improvement in recognition by SR141716A was associated
with increases in the levels of NA and 5-HT in the prefrontal
cortex.
5. Conclusions
In conclusion, the preponderance of data presented here
suggests some relationship between the acute eﬀects of
SR141716A on the forced swim and social recognition tests
and a therapeutic potential in the treatment of behavioral
alterationsinPD,furtherstrengtheningthetherapeuticvalue
of this CB1 receptor antagonist which was already proposed
for the treatment of motor impairments in PD [12, 29].
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